ACRX - AcelRx Pharmaceuticals, Inc.
| Previous Close | 2.45 |
| Open | 2.40 |
| Bid | 2.35 x 1000 |
| Ask | 2.40 x 1000 |
| Day's Range | 2.35 - 2.40 |
| 52 Week Range | 1.55 - 5.75 |
| Volume | 219,069 |
| Avg. Volume | 448,538 |
| Market Cap | 119.613M |
| Beta | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.10 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.42 |
- ACCESSWIRE•3 days ago
Blog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIA
LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) ("AcelRx").If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ACRX as the Company's latest news hit the wire. On April 16, 2018, the specialty pharmaceutical Company, which is focused on the development and commercialization of innovative therapies for the treatment of acute pain, declared the successful completion of the human factor study to validate the effectiveness of the revised DSUVIA directions for use (DFU).
- PR Newswire•3 days ago
AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting
REDWOOD CITY, Calif. , April 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- PR Newswire•5 days ago
AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018
REDWOOD CITY, Calif. , April 16, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in ...
- PR Newswire•10 days ago
AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe
REDWOOD CITY, Calif., April 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported the publication of a report commissioned by AcelRx analyzing the economic burden associated with administration of intravenous (IV) morphine for acute pain in the emergency department (ED) in the peer-reviewed journal Drugs in Context. This manuscript reports on the results of a micro-costing analysis to estimate the burden of IV administration of morphine in five key European countries based on a literature review.
- PR Newswire•25 days ago
AcelRx announces appointment of John Saia as General Counsel
REDWOOD CITY, Calif. , March 27, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on innovative ...
- ACCESSWIRE•26 days ago
Blog Exposure - FDA Cleared Orthofix International’s G-Beam Fusion Beaming System
Stock Monitor: AcelRx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free research report on Orthofix International N.V. (NASDAQ: OFIX ...
- Simply Wall St.•last month
When Can We Expect A Profit From AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)?
AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX): AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The US$101.80M market-cap company announcedRead More...
- Thomson Reuters StreetEvents•last month
Edited Transcript of ACRX earnings conference call or presentation 8-Mar-18 9:30pm GMT
Q4 2017 AcelRx Pharmaceuticals Inc Earnings Call
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and TherapeuticsMD
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Biotech stocks AcelRx and TherapeuticsMD both saw gains on Thursday with the gains extended into after-hours trading. AcelRx moved higher despite reporting a ...
- Associated Press•last month
AcelRx Pharmaceuticals reports 4Q loss
The Redwood City, California-based company said it had a loss of 20 cents per share. The drugmaker posted revenue of $740,000 in the period. For the year, the company reported that its loss widened to ...
- PR Newswire•last month
AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results
- FDA Type A meeting in January 2018 provides path to DSUVIA™ NDA resubmission expected in Q2 2018 - $60.5 million of cash and short-term investments at December 31, 2017 - Q4 2017 combined G&A and R&D ...
- PR Newswire•last month
AcelRx announces receipt of Type A FDA meeting minutes and plans to resubmit the DSUVIA New Drug Application in Q2 2018
REDWOOD CITY, Calif. , March 8, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in ...
- ACCESSWIRE•last month
AcelRx Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 4:30 PM Eastern ...
- Zacks•last month
Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?
Surging implied volatility makes AcelRx Pharmaceuticals (ACRX) lucrative to the option traders.
- PR Newswire•2 months ago
AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March
REDWOOD CITY, Calif. , March 5, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
- PR Newswire•2 months ago
AcelRx Pharmaceuticals to Hold Annual 2017 Financial Results Conference Call and Webcast on Thursday, March 8th, 2018
REDWOOD CITY, Calif. , March 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and yearly financial ...
- GlobeNewswire•2 months ago
Research Report Identifies Pinnacle Financial Partners, Tribune Media, Ollie's Bargain Outlet, International Flavors & Fragrances, Harris, and AcelRx Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pinnacle ...
- PR Newswire•2 months ago
AcelRx Pharmaceuticals to Present at 2018 RBC Capital Markets Global Healthcare Conference
REDWOOD CITY, Calif. , Feb. 16, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
- Zacks•4 months ago
Omeros Inks Agreement With FDA for OMS721 Phase III Trial
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
- Zacks•4 months ago
Merck's Keytruda Gets Approved for Bladder Cancer in Japan
Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.
- Simply Wall St.•4 months ago
AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) Earnings Declined -16.55%, But How Did It Fare Against The Industry?
Examining AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...
- Zacks•4 months ago
5 Reasons to Pick Emergent as an Investment-Worthy Stock
Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.
- Zacks•4 months ago
Actinium Posts Positive DMC View on Lomab-B Phase III Trial
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
- ACCESSWIRE•4 months ago
Free Research Report as Masimo’s Revenue Jumped 15.6%; EPS Surged 35%
Stock Monitor: AcelRx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 08, 2017 / Active-Investors free earnings report on Masimo Corp. (NASDAQ: MASI ) has freshly been issued to its members, ...
